Regenerative Medicine
다른 이름: 재생의료, 재생의학, 첨단재생의료, RMAT
Regenerative medicine is a field that aims to repair, replace or regenerate damaged cells, tissues or organs, using approaches such as cell therapy, tissue engineering and biomaterials.
Is SVF treatment approved in Korea?
In South Korea, advanced regenerative medicine is governed by a dedicated framework: institutions conducting it must be designated by the Ministry of Health and Welfare and cell processing facilities need permission from the Ministry of Food and Drug Safety. Whether a specific SVF procedure is permitted depends on how the cells are processed and used. Ask the clinic for its designation and permission documents and check them with the regulator.
핵심 사실
| 항목 | 값 | 출처 |
|---|---|---|
| Definition | Replacement or regeneration of human cells, tissues or organs to restore or establish normal function | [3]journalRegenerative medicine: Historical roots and potential strategies in modern medicineJournal of Microscopy and Ultrastructure (via PubMed Central, NIH) |
| Origin of the term | Popularized by William Haseltine at a 1999 conference on Lake Como; first used by Leland Kaiser in a 1992 paper | [3]journalRegenerative medicine: Historical roots and potential strategies in modern medicineJournal of Microscopy and Ultrastructure (via PubMed Central, NIH) |
| Main approaches | Cell-based therapy (differentiated or stem cells), biomaterial scaffolds, and cell-seeded scaffolds (tissue engineering) | [3]journalRegenerative medicine: Historical roots and potential strategies in modern medicineJournal of Microscopy and Ultrastructure (via PubMed Central, NIH) |
| Treatment allowed in South Korea | Since the amendment took effect on 2025-02-21, advanced regenerative medicine treatment is allowed for patients with life-threatening, rare or intractable conditions that have no alternative therapy기준 2025년 2월 21일 | [4]industry첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률의 개정 및 시행과 그 시사점법무법인(유) 세종 |
| Clinical research scope in South Korea | 2025 amendment removed the limit that restricted clinical research participants to patients with serious, rare or intractable diseases기준 2025년 2월 21일 | [4]industry첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률의 개정 및 시행과 그 시사점법무법인(유) 세종 |
| U.S. legal definition (RMAT) | A cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination of these; certain human gene therapies and xenogeneic cell products may also qualify (FD&C Act section 506(g))기준 2025년 11월 4일 | [5]governmentRegenerative Medicine Advanced Therapy DesignationU.S. Food and Drug Administration |
| RMAT designation criteria | Must be a regenerative medicine therapy intended for a serious or life-threatening condition, with preliminary clinical evidence of potential to address unmet medical needs (21st Century Cures Act section 3033)기준 2025년 11월 4일 | [5]governmentRegenerative Medicine Advanced Therapy DesignationU.S. Food and Drug Administration |
| FDA consumer warning | FDA warns that stem cells, stromal vascular fraction, cord blood, amniotic fluid, Wharton's jelly and exosome products marketed outside clinical trials without licensure are illegal; being listed on ClinicalTrials.gov or registered with the FDA does not mean a product is approved | [6]governmentImportant Patient and Consumer Information About Regenerative Medicine TherapiesU.S. Food and Drug Administration |
| Regulators (Korea) | Ministry of Health and Welfare (institution designation) and Ministry of Food and Drug Safety (products, cell processing facilities) | [1]governmentMinistry of Food and Drug Safety — English siteMFDS, Republic of Korea |
| Regulator (US) | U.S. Food and Drug Administration | [2]governmentFDA Warns About Stem Cell TherapiesU.S. Food and Drug Administration |
개요
Regenerative medicine is a field of medicine that aims to replace or regenerate human cells, tissues or organs so that they work normally again. Its main approaches are cell-based therapy (including stem cells), biomaterial scaffolds and tissue engineering, and certain gene therapies. Hematopoietic stem cell transplantation is established practice, but many other uses are still investigational. In the United States, the FDA regulates these products and can grant Regenerative Medicine Advanced Therapy (RMAT) designation under the 21st Century Cures Act. In South Korea, the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act took effect in August 2020. Since a 2025 amendment, it has allowed treatment, not only clinical research, for serious, rare or intractable conditions that lack alternative therapies. Before any treatment, readers should confirm the product's approval or trial status directly with the regulator.
검증 프로바이더
유료 노출은 표시됩니다. 검증은 결제와 무관합니다.SC301의원
SC301의원 (SC301 Clinic) is a plastic surgery clinic in Gangnam, Seoul, South Korea whose official site presents SVF (stromal vascular fraction) fat grafting for the breast and face, liposuction, lifting and cell banking as its main services.
프로바이더 보기참고 출처
독립 출처 비율 87% (13/15)- 등급 A · governmentMinistry of Food and Drug Safety — English site — MFDS, Republic of Korea · 확인일 2026년 9월 22일 · 근거 페이지
- 등급 A · governmentFDA Warns About Stem Cell Therapies — U.S. Food and Drug Administration · 확인일 2026년 9월 15일 · 근거 페이지
- 등급 B · journalRegenerative medicine: Historical roots and potential strategies in modern medicine — Journal of Microscopy and Ultrastructure (via PubMed Central, NIH) · 확인일 2026년 11월 11일 · 근거 페이지
- 등급 D · industry첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률의 개정 및 시행과 그 시사점 — 법무법인(유) 세종 · 확인일 2026년 11월 10일 · 근거 페이지
- 등급 A · governmentRegenerative Medicine Advanced Therapy Designation — U.S. Food and Drug Administration · 확인일 2026년 11월 10일 · 근거 페이지
- 등급 A · governmentImportant Patient and Consumer Information About Regenerative Medicine Therapies — U.S. Food and Drug Administration · 확인일 2026년 11월 10일 · 근거 페이지
- 등급 A · governmentStem Cell Basics — National Institutes of Health (NIH) · 확인일 2026년 9월 15일 · 근거 페이지
- 등급 C · organizationISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research · 확인일 2026년 11월 12일 · 근거 페이지
- 등급 C · organizationAbout Stem Cells — patient resource — International Society for Stem Cell Research · 확인일 2026년 11월 12일 · 근거 페이지
- 등급 B · academicSafety profile of autologous adipose-derived stromal vascular fraction in clinical use: an exhaustive literature review — Stem Cell Research & Therapy (2026) · 확인일 2026년 11월 12일 · 근거 페이지
- 등급 A · government再生・細胞医療・遺伝子治療について（再生医療等安全性確保法・再生医療等提供計画・認定再生医療等委員会） — 厚生労働省 · 확인일 2026년 11월 12일 · 근거 페이지
- 등급 A · government再生医療等提供機関の情報について — 厚生労働省 · 확인일 2026년 11월 12일 · 근거 페이지
- 등급 A · government再生医療等製品（承認品目・審査報告書） — 独立行政法人 医薬品医療機器総合機構（PMDA） · 확인일 2026년 10월 11일 · 근거 페이지
- organization幹細胞を用いた自由診療についての日本再生医療学会からの声明 — 一般社団法人 日本再生医療学会 · 확인일 2026년 11월 12일 · 근거 페이지
- organization再生医療等の自由診療における広告に関する注意喚起について — 一般社団法人 日本再生医療学会 · 확인일 2026년 11월 12일 · 근거 페이지